SG11201809374VA - Cd40l-fc fusion polypeptides and methods of use thereof - Google Patents

Cd40l-fc fusion polypeptides and methods of use thereof

Info

Publication number
SG11201809374VA
SG11201809374VA SG11201809374VA SG11201809374VA SG11201809374VA SG 11201809374V A SG11201809374V A SG 11201809374VA SG 11201809374V A SG11201809374V A SG 11201809374VA SG 11201809374V A SG11201809374V A SG 11201809374VA SG 11201809374V A SG11201809374V A SG 11201809374VA
Authority
SG
Singapore
Prior art keywords
international
gaithersburg
llc
medimmune
way
Prior art date
Application number
SG11201809374VA
Inventor
Manuel Baca
Stacey Drabic
Peter Emtage
Ronald Herbst
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201809374VA publication Critical patent/SG11201809374VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit VIII mum 0101111E0m0111 Dl Imo oimIE (10) International Publication Number WO 2017/197231 Al (51) International Patent Classification: C07K 19/00 (2006.01) A61K 38/00 (2006.01) (21) International Application Number: PCT/US2017/032352 (22) International Filing Date: 12 May 2017 (12.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/336,129 13 May 2016 (13.05.2016) US (71) Applicant: MEDIMMUNE, LLC [US/US]; One Medim- mune Way, Gaithersburg, MD 20878 (US). (72) Inventors: BACA, Manuel; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). DRABIC, Stacey; c/o MedImmune, LLC, One Medlm- mune Way, Gaithersburg, MD 20878 (US). EMTAGE, Pe- ter; c/o Cell Design Labs, QB3@953 Indiana Street, San Francisco, CA 94107 (US). HERBST, Ronald; c/o Medlm- mune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). (74) Agent: DISE, Rebecca, S. et al.; c/o MedImmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) N N (54) Title: CD4OL-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF 1-1 0 (57) : Provided herein is a CD4OL-Fc fusion protein and methods of using the fusion protein in the treatment of cancer \" comprising administering the CD4OL-Fc fusion protein or the CD4OL-Fc fusion protein in combination with one or more immune 0 checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-Ll antibody).
SG11201809374VA 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof SG11201809374VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13
PCT/US2017/032352 WO2017197231A1 (en) 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201809374VA true SG11201809374VA (en) 2018-11-29

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809374VA SG11201809374VA (en) 2016-05-13 2017-05-12 Cd40l-fc fusion polypeptides and methods of use thereof

Country Status (18)

Country Link
US (1) US10975155B2 (en)
EP (1) EP3455263A4 (en)
JP (1) JP2019523636A (en)
KR (1) KR20190004319A (en)
CN (1) CN109153729A (en)
AR (1) AR108468A1 (en)
AU (1) AU2017264944A1 (en)
BR (1) BR112018072953A2 (en)
CA (1) CA3022636A1 (en)
CL (1) CL2018003141A1 (en)
CO (1) CO2018013104A2 (en)
IL (1) IL262727A (en)
MA (1) MA44993A (en)
MX (1) MX2018013762A (en)
RU (1) RU2018138703A (en)
SG (1) SG11201809374VA (en)
TW (1) TW201741337A (en)
WO (1) WO2017197231A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571879T3 (en) * 2008-07-21 2016-05-27 Apogenix Ag TNFSF single chain molecules
WO2015036499A1 (en) * 2013-09-11 2015-03-19 Medimmune Limited Anti-b7-h1 antibodies for treating tumors
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
HRP20230937T1 (en) 2017-01-05 2023-11-24 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
HUE057326T2 (en) 2017-01-05 2022-04-28 Kahr Medical Ltd A sirp1 alpha-41bbl fusion protein and methods of use thereof
US20220135649A1 (en) * 2019-02-06 2022-05-05 The Regents Of The University Of California Dominant negative cd40l polypeptides
KR20210006301A (en) * 2019-07-08 2021-01-18 주식회사 프로젠 A novel fusion protein and use thereof
WO2021149945A1 (en) * 2020-01-23 2021-07-29 주식회사 제넥신 Fusion protein comprising pd-l1 protein and use thereof
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222914C (en) * 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
EA004401B1 (en) * 1996-07-08 2004-04-29 Дзе Трастиз Оф Колумбия Юниверсити Ин Дзе Сити Оф Нью Йорк Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
CN1461344A (en) * 2000-07-25 2003-12-10 免疫医疗公司 Multivalent target binding protein
DE60227285D1 (en) 2001-12-21 2008-08-07 Immunex Corp RECOMBINANT POLYPEPTIDE
NZ563392A (en) * 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
ES2571879T3 (en) * 2008-07-21 2016-05-27 Apogenix Ag TNFSF single chain molecules
MA41460A (en) * 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
JP6738831B2 (en) * 2015-05-04 2020-08-12 アポジェニックス アーゲー Single chain CD40 receptor agonist protein

Also Published As

Publication number Publication date
EP3455263A1 (en) 2019-03-20
CL2018003141A1 (en) 2018-12-28
CN109153729A (en) 2019-01-04
CO2018013104A2 (en) 2018-12-14
AR108468A1 (en) 2018-08-22
EP3455263A4 (en) 2020-01-01
WO2017197231A1 (en) 2017-11-16
AU2017264944A1 (en) 2018-12-20
MX2018013762A (en) 2019-03-28
RU2018138703A (en) 2020-06-15
TW201741337A (en) 2017-12-01
MA44993A (en) 2019-03-20
JP2019523636A (en) 2019-08-29
KR20190004319A (en) 2019-01-11
CA3022636A1 (en) 2017-11-16
US10975155B2 (en) 2021-04-13
US20170327588A1 (en) 2017-11-16
IL262727A (en) 2018-12-31
BR112018072953A2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811184UA (en) Lag -3 binding members
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201900442PA (en) Sorting of t lymphocytes in a microfluidic device
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof